As shown in Fig. 1E, the outcomes indicated that KLF16 stood as a significant risk factor for the CSS of patients with BLCA (Hazard ratio = 0.490, 95% CI: 0.283–0.847, P = 0.011). This evidence concerns the gene KLF16 and bladder transitional cell carcinoma.